No Data
Collegium Pharmaceutical (NASDAQ:COLL) Shareholders Have Earned a 19% CAGR Over the Last Five Years
Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity
Collegium Pharmaceutical (COLL) said Thursday that the US Food and Drug Administration granted pediatric exclusivity for Nucynta and Nucynta ER, extending the exclusivity period for the Nucynta franch
Express News | Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Street Calls of the Week: Upgrades for Best Buy and Lululemon
Collegium Pharmaceutical Raised to Buy From Hold by Jefferies
Collegium Pharmaceutical Raised to Buy From Hold by Jefferies